New drug combo targets advanced colorectal cancer in major trial
NCT ID NCT07283367
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination (HS-20110) in about 502 adults with advanced colorectal cancer that has not responded to prior treatments. The goal is to find the safest and most effective dose and see if it can shrink tumors. Participants must have a specific type of cancer (non-MSI-H, no BRAF V600E mutation) and at least one measurable tumor.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may let cancer patients take safe breaks from immunotherapy
- Pee test could spot colon cancer early in africa
- Sniffing out cancer: new breath test could spot colon cancer before it spreads
- New biopsy method may predict cancer spread without surgery
- New combo therapy shows promise for Tough-to-Treat colon cancer
- Cancer combo trial pulled before it even started